SEC Comment Letter for Jaguar Health, Inc. (JAGX) (CIK 0001585608) (JAGX) — Feb 12, 2018
Jaguar Health, Inc. (JAGX) (CIK 0001585608)
Date: Feb. 12, 2018 · CIK: 0001585608 · Accession: 0000000000-18-004838
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36714
Letter
February 12, 2018 Lisa A. Conte Chief Executive Officer and President Jaguar Health, Inc. 201 Mission Street, Suite 2375 San Francisco, California 94105 Re:Jaguar Health, Inc. Preliminary Proxy Statement on Schedule 14A Filed February 6, 2018 File No. 001-36714 Dear Ms. Conte: We have limited our review of your filing to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Preliminary Proxy Statement on Schedule 14A Proposal 1, page 8 1.Please expand your disclosure to specifically state whether you have any plans, proposals or arrangements, written or oral, to issue any of the newly authorized shares of common stock for general corporate or any other purposes. Please provide similar disclosure for Proposal 2 with respect to the newly authorized shares that will available as a result of the reverse stock split if that proposal is approved. If there are any such plans, please describe them. Proposal 3, page 19 2.Please disclose the maximum amount of discount to the market at which shares may be issued.
FirstName LastNameLisa A. Conte Comapany NameJaguar Health, Inc. June 16, 2017 Page 2 FirstName LastName Lisa A. Conte Jaguar Health, Inc. February 12, 2018 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 or Mary Beth Breslin at (202) 551-3625 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Donald C. Reinke, Esq.
Show Raw Text
February 12, 2018
Lisa A. Conte
Chief Executive Officer and President
Jaguar Health, Inc.
201 Mission Street, Suite 2375
San Francisco, California 94105
Re:Jaguar Health, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed February 6, 2018
File No. 001-36714
Dear Ms. Conte:
We have limited our review of your filing to those issues we have addressed in
our comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A
Proposal 1, page 8
1.Please expand your disclosure to specifically state whether you have any plans, proposals
or arrangements, written or oral, to issue any of the newly authorized shares of common
stock for general corporate or any other purposes. Please provide similar disclosure for
Proposal 2 with respect to the newly authorized shares that will available as a result of the
reverse stock split if that proposal is approved. If there are any such plans, please describe
them.
Proposal 3, page 19
2.Please disclose the maximum amount of discount to the market at which shares may be
issued.
FirstName LastNameLisa A. Conte
Comapany NameJaguar Health, Inc.
June 16, 2017 Page 2
FirstName LastName
Lisa A. Conte
Jaguar Health, Inc.
February 12, 2018
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Chris Edwards at (202) 551-6761 or Mary Beth Breslin at (202) 551-3625
with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Donald C. Reinke, Esq.